Related Experiment Video
Updated: Apr 24, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling
Catherine A Del Vecchio1, Yuxiong Feng1, Ethan S Sokol2
1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America.
Abstract:
Malignant carcinomas that recur following therapy are typically de-differentiated and multidrug resistant (MDR). De-differentiated cancer cells acquire MDR by up-regulating reactive oxygen species (ROS)-scavenging enzymes and drug efflux pumps, but how these genes are up-regulated in response to de-differentiation is not known. Here, we examine this question by using global transcriptional profiling to identify ROS-induced genes that are already up-regulated in de-differentiated cells, even in the absence of oxidative damage. Using this approach, we found that the Nrf2 transcription factor, which is the master regulator of cellular responses to oxidative stress, is preactivated in de-differentiated cells. In de-differentiated cells, Nrf2 is not activated by oxidation but rather through a noncanonical mechanism involving its phosphorylation by the ER membrane kinase PERK. In contrast, differentiated cells require oxidative damage to activate Nrf2. Constitutive PERK-Nrf2 signaling protects de-differentiated cells from chemotherapy by reducing ROS levels and increasing drug efflux. These findings are validated in therapy-resistant basal breast cancer cell lines and animal models, where inhibition of the PERK-Nrf2 signaling axis reversed the MDR of de-differentiated cancer cells. Additionally, analysis of patient tumor datasets showed that a PERK pathway signature correlates strongly with chemotherapy resistance, tumor grade, and overall survival. Collectively, these results indicate that de-differentiated cells up-regulate MDR genes via PERK-Nrf2 signaling and suggest that targeting this pathway could sensitize drug-resistant cells to chemotherapy.
Insights
De-differentiated cancers develop multidrug resistance (MDR) through PERK-Nrf2 signaling, not oxidative stress. Targeting this pathway can re-sensitize resistant cancer cells to chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Stress Response
Background:
- Recurrent malignant carcinomas often exhibit de-differentiation and multidrug resistance (MDR).
- The mechanisms by which de-differentiated cancer cells acquire MDR, including upregulation of reactive oxygen species (ROS)-scavenging enzymes and drug efflux pumps, remain unclear.
- Understanding the regulation of these genes during de-differentiation is crucial for overcoming therapeutic resistance.
Purpose of the Study:
- To identify ROS-induced genes upregulated in de-differentiated cells independent of oxidative damage.
- To elucidate the signaling pathway responsible for preactivating the Nrf2 transcription factor in de-differentiated cancer cells.
- To investigate the therapeutic potential of targeting this pathway in drug-resistant cancers.
Main Methods:
- Global transcriptional profiling to identify upregulated genes in de-differentiated cells.
- Analysis of the Nrf2 transcription factor activation mechanism in differentiated versus de-differentiated cells.
- Experimental validation in basal breast cancer cell lines and animal models.
- Correlation analysis of PERK pathway signature with clinical data from patient tumor datasets.
Main Results:
- Nrf2, a master regulator of oxidative stress response, is preactivated in de-differentiated cells via a noncanonical mechanism involving PERK-mediated phosphorylation, independent of oxidative damage.
- This constitutive PERK-Nrf2 signaling confers MDR by reducing ROS levels and increasing drug efflux.
- Inhibition of the PERK-Nrf2 pathway reversed MDR in therapy-resistant basal breast cancer models.
- A PERK pathway signature in patient tumors strongly correlates with chemotherapy resistance, higher tumor grade, and poorer overall survival.
Conclusions:
- De-differentiated cancer cells utilize a PERK-Nrf2 signaling axis to upregulate MDR genes, distinct from canonical oxidative stress responses.
- Targeting the PERK-Nrf2 pathway presents a promising strategy to overcome chemotherapy resistance in de-differentiated and multidrug-resistant cancers.
- This pathway serves as a potential biomarker for predicting treatment response and patient prognosis.
More Related Videos
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Transduction
Treatment Resistant Cancers
Desensitization and Tachyphylaxis
GPCR Desensitization
Diversity in Cell Signaling Responses
Graded and Abrupt Responses
Some signaling systems generate...

